Seeking volunteers for Schizophrenia Research Study - Join Now!
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA
1.Patients are male or female, 18 to 64 years of age, inclusive;
2.Diagnosis of schizophrenia for a minimum of 1 year;
3.Must have an identified external contact person or an identified responsible person (eg, family member, friend, social worker, case worker, or nurse) who is considered reliable.